Trial Profile
Phase II study of gefitinib combined with carboplatin/pemetrexed for elderly patients with EGFR mutated advanced non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2019
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Aug 2019 Status changed from recruiting to discontinued.
- 23 Apr 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
- 05 Feb 2015 New trial record